e-learning
resources
Amsterdam 2015
Monday, 28.09.2015
The immunology of allergic airway disease
Login
Search all ERS
e-learning
resources
Disease Areas
Airways Diseases
Interstitial Lung Diseases
Respiratory Critical Care
Respiratory Infections
Paediatric Respiratory Diseases
Pulmonary Vascular Diseases
Sleep and Breathing Disorders
Thoracic Oncology
Events
International Congress
Courses
Webinars
Conferences
Research Seminars
Journal Clubs
Publications
Breathe
Monograph
ERJ
ERJ Open Research
ERR
European Lung White Book
Handbook Series
Guidelines
All ERS guidelines
e-learning
CME Online
Case reports
Short Videos
SpirXpert
Procedure Videos
CME tests
Reference Database of Respiratory Sounds
Radiology Image Challenge
Brief tobacco interventions
EU Projects
VALUE-Dx
ERN-LUNG
ECRAID
UNITE4TB
Disease Areas
Events
Publications
Guidelines
e-learning
EU Projects
Login
Search
TNF-α, IL-6, IL-10 serum activity in patients with obesity-associated arterial hypertension depend on bronchial obstruction presence
Kseniia Sytnyk (Kharkiv, Ukraine), Kseniia Sytnyk, Butov Dmytro
Source:
International Congress 2015 – The immunology of allergic airway disease
Session:
The immunology of allergic airway disease
Session type:
Thematic Poster Session
Number:
2563
Disease area:
Airway diseases
Rating:
You must
login
to grade this presentation.
Share or cite this content
Citations should be made in the following way:
Kseniia Sytnyk (Kharkiv, Ukraine), Kseniia Sytnyk, Butov Dmytro. TNF-α, IL-6, IL-10 serum activity in patients with obesity-associated arterial hypertension depend on bronchial obstruction presence. Eur Respir J 2015; 46: Suppl. 59, 2563
You must
login
to share this Presentation/Article on Twitter, Facebook, LinkedIn or by email.
Member's Comments
No comment yet.
You must
Login
to comment this presentation.
Related content which might interest you:
Panel discussion on Basic translational and clinical research – building a career in paediatric pulmonology- experiences from clinicians in lower middle income countries
Panel discussion on ERS Statement – A core outcome set for clinical trials evaluating the management of COPD exacerbations
ERS statement: a core outcome set for clinical trials evaluating the management of COPD exacerbations
Related content which might interest you:
The level of anti-inflammatory cytokine IL-10 in patients with chronic obstructive pulmonary disease of varying severity
Source: Annual Congress 2013 –COPD: new markers of diseases
Year: 2013
Role of systemic inflammation mediated by IL-6 and TNF-alpha cytokines in chronic obstructive pulmonary disease and its progression: A three year follow up study
Source: Annual Congress 2013 –Systemic and airway biomarkers in respiratory diseases
Year: 2013
Serum levels of leptin and visfatin in chronic obstructive pulmonary disease
Source: International Congress 2015 – Different data in COPD
Year: 2015
MIG and IP-10 levels in induced sputum of stable and exacerbated COPD patients
Source: International Congress 2015 – Systemic and airway biomarkers
Year: 2015
Production of proinflammation cytokines and mean pulmonary arterial pressure in COPD
Source: Annual Congress 2013 –The vulnerable patient and ageing cells
Year: 2013
IL-17A is elevated in patients with COPD and contributes to airway remodeling by acting on fibroblasts
Source: International Congress 2016 – What's new in biomarker analysis?
Year: 2016
Increased serum level of apelin in chronic obstructive pulmonary disease
Source: International Congress 2015 – COPD: interesting notes
Year: 2015
Cytokines and MMP-9 level in serum and induced sputum of patients with suspicion of occupational COPD
Source: International Congress 2016 – Occupational and environmental exposures and biomarkers: human studies, animal data, and in vitro methods
Year: 2016
Serum levels of RAAS components in COPD
Source: International Congress 2015 – Non-exhaled biomarkers in the assessment of airways disease
Year: 2015
Increased total serum levels of ghrelin and nesfatin in chronic obstructive pulmonary disease
Source: International Congress 2015 – Notable abstracts in exacerbations, mechanisms and biomarkers in COPD
Year: 2015
Can leptin and IL-6 influence the nutritional status in COPD patients?
Source: Annual Congress 2006 - COPD and systemic inflammation
Year: 2006
Potential association between pulmonary hypertension in COPD and monocyte chemoattractant protein (MCP)-1
Source: Annual Congress 2005 - Pulmonary hypertension: pathophysiology
Year: 2005
Serum IL-17 and IL-18 levels in asthma-COPD overlap syndrome patients
Source: International Congress 2015 – Promising novel findings in translational pulmonary research
Year: 2015
New anti-inflammatory activities of Alpha-1-Antitrypsin and their role in COPD
Source: Annual Congress 2005 - Protease-antiprotease revisited
Year: 2005
Regulation of inflammation process in chronic thromboembolic pulmonary hypertension: a potential role of platelet-activating factor-acetylhydrolase
Source: Annual Congress 2006 - Pulmonary circulation: inflammation and remodelling
Year: 2006
Elevated circulating CTLA-4 level in patients with COPD is related to systemic inflammation and disease severity
Source: Annual Congress 2013 –COPD: markers and inflammation
Year: 2013
Pathology, inflammation and cytokines of severe asthma
Source: Eur Respir Mon 2011; 51: 97-106
Year: 2011
Mediation of the effect of airflow obstruction upon six minute Walking distance (6MWD) by cytokine IL6 plasma levels in chronic obstructive pulmonary disease (COPD)
Source: Annual Congress 2013 –COPD treatment and others
Year: 2013
Concentration of IL-2, IL-4, IL-8 and TNF in blood serum and sputum in bronchial asthma and chronic obstructive pulmonary disease
Source: Annual Congress 2009 - Inflammation and airways
Year: 2009
Aerobic exercise reduces pulmonary inflammation in diet-induced obesity in a HDM model of asthma through adipokines, IL-10, IL-17 and IL-23 signaling
Source: International Congress 2015 – New insights into exercise and muscle performance
Year: 2015
We use cookies on our website to give you the most relevant experience by remembering your preferences and repeat visits. By clicking "Accept", you consent to the use of the cookies.
Accept